YL-15293
KRAS G12C Cancer
Phase 1Active
Key Facts
About 280Bio
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profileKRAS G12C Cancer
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profile